A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 4, 2013

Study Completion Date

June 7, 2013

Conditions

Macular Degeneration

Interventions

DRUG

ALG 1001

Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.

Trial Locations (1)

APEC Hospital La Ceguera, Mexico City